4-amino-5-(4-bromobenzyl)-4H-1,2,4-triazole-3-thiol | 151297-85-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-amino-5-(4-bromobenzyl)-4H-1,2,4-triazole-3-thiol
• 英文别名: 4-amino-3-[(4-bromophenyl)methyl]-1H-1,2,4-triazole-5-thione
• CAS: 151297-85-7
• 化学式: C₉H₉BrN₄S
• mdl: MFCD03986047
• 分子量: 285.167
• InChiKey: DDZFKCBKISTXMM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  85.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-amino-5-(4-bromobenzyl)-4H-1,2,4-triazole-3-thiol 、 3-bromo-4-(4-chloro-phenyl)-4-oxo-butyric acid ethyl ester 以 乙醇 为溶剂， 以60 %的产率得到ethyl 2-(3-(4-bromobenzyl)-6-(4-chlorophenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazin-7-yl)acetate
  参考文献：
  名称：

  Discovery of a non-covalent ligand for Rpn-13, a therapeutic target for hematological cancers

  摘要：

  DOI：

  10.1016/j.bmcl.2023.129485
• 作为产物：
  描述：

  在 硫化氢 、 一水合肼 作用下， 以 水 为溶剂， 以60 %的产率得到4-amino-5-(4-bromobenzyl)-4H-1,2,4-triazole-3-thiol
  参考文献：
  名称：

  Discovery of a non-covalent ligand for Rpn-13, a therapeutic target for hematological cancers

  摘要：

  DOI：

  10.1016/j.bmcl.2023.129485

文献信息

• INHIBITORS OF UDP-GALACTOPYRANOSE MUTASE
  申请人：WISCONSIN ALUMNI RESEARCH FOUNDATION

  公开号：US20170258805A1

  公开（公告）日：2017-09-14

  Compounds and salts thereof which are acyl-sulfonamides or certain carboxylic acids and which inhibit microbial growth or attenuate the virulence of pathogenic microorganisms and which inhibit UDP-galactopyranose mutase (UGM). Compounds of the invention include 2-aminothiazoles and triazolothiadiazines, particularly 3,6,7-substituted-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines, and 2-amino and salts thereof. Methods for inhibiting growth or attenuating virulence of microbial pathogens including mycobacterium , for example, M. tuberculosis and M. smegmatis and Klebsiella , for example, Klebsiella pneumoniae . Methods for inhibiting eukaryotic human and animal pathogens, and fungi and nematodes in particular. Methods for treatment of infections by prokaryotic and eukaryotic pathogens employing compounds of the invention.

  其酰基磺酰胺或某些羧酸的化合物及其盐，能够抑制微生物生长或减弱病原微生物的毒力，并且能够抑制UDP-半乳糖吡喃糖异构酶（UGM）。该发明的化合物包括2-氨基噻唑和三唑噻二嗪，特别是3,6,7-取代的7H-[1,2,4]三唑噻二嗪和其盐，以及2-氨基。抑制微生物病原体生长或减弱其毒力的方法包括结核分枝杆菌（例如结核分枝杆菌和平滑分枝杆菌）和克雷伯氏菌（例如肺炎克雷伯氏菌）等微生物病原体。抑制真核人类和动物病原体、真菌和线虫的方法，特别是治疗原核和真核病原体感染的方法，采用了该发明的化合物。
• Inhibitors of UDP-galactopyranose mutase
  申请人：WISCONSIN ALUMNI RESEARCH FOUNDATION

  公开号：US10080757B2

  公开（公告）日：2018-09-25

  Compounds and salts thereof which are acyl-sulfonamides or certain carboxylic acids and which inhibit microbial growth or attenuate the virulence of pathogenic microorganisms and which inhibit UDP-galactopyranose mutase (UGM). Compounds of the invention include 2-aminothiazoles and triazolothiadiazines, particularly 3,6,7-substituted-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines, and 2-amino and salts thereof. Methods for inhibiting growth or attenuating virulence of microbial pathogens including mycobacterium, for example, M. tuberculosis and M. smegmatis and Klebsiella, for example, Klebsiella pneumoniae. Methods for inhibiting eukaryotic human and animal pathogens, and fungi and nematodes in particular. Methods for treatment of infections by prokaryotic and eukaryotic pathogens employing compounds of the invention.

  本发明的化合物及其盐类为酰基磺酰胺类或某些羧酸类，可抑制微生物生长或减弱病原微生物的毒力，并可抑制UDP-半乳糖吡喃糖突变酶（UGM）。本发明的化合物包括 2-氨基噻唑和三唑并噻二嗪，特别是 3,6,7-取代的-7H-[1,2,4]三唑并[3,4-b][1,3,4]噻二嗪及其 2-氨基和盐。抑制微生物病原体生长或减弱其毒性的方法，这些微生物病原体包括分枝杆菌（例如结核杆菌和烟曲霉菌）和克雷伯氏菌（例如肺炎克雷伯氏菌）。抑制真核人类和动物病原体，特别是真菌和线虫的方法。利用本发明化合物治疗原核和真核病原体感染的方法。
• Acetylcholinesterase inhibition activity of some quinolinyl substituted triazolothiadiazole derivatives
  作者：Muhammad Rafiq、Muhammad Saleem、Muhammad Hanif、Qamar Abbas、Ki Hwan Lee、Sung-Yum Seo

  DOI：10.1134/s1068162015020089

  日期：2015.3

  A series of aralkanoic acids was converted into aralkanoic acid hydrazides through their esters formation. The aralkanoic acid hydrazides upon treatment with carbon disulfide and methanolic potassium hydroxide yielded potassium dithiocarbazinate salts, which on refluxing with aqueous hydrazine hydrate yielded 5-aralkyl-4-amino-3-mercapto-1,2,4-triazoles. The target compounds, 3-aralkyl-6-(substitutedquinolinyl) [1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles, were synthesized by condensing various quinolinyl substituted carboxylic acids with 5-aralkyl-4-amino-3-mercapto-1,2,4-triazoles in phosphorus oxychloride. The structures of the newly synthesized triazolothiadiazoles were characterized by IR, H-1 NMR, C-13 NMR, and elemental analysis studies. The structure of one of the 5-aralkyl-4-amino-3-mercapto-1,2,4-triazoles was unambiguously deduced by single crystal X-ray diffraction analysis. All the synthesized compounds were screened for their acetylcholinesterase inhibition activities. Four of the triazolothiadiazoles exhibited excellent acetylcholinesterase inhibition activities as compared to the reference inhibitor.